Search results for "Agoni"

showing 10 items of 2493 documents

Time-related effects of thyrotropin-releasing hormone (TRH) on the pituitary-thyroid axis and extrathyroidal targets.

2009

Thyrotropin-releasing hormone (TRH) is a tripeptide and acts as a stimulator of the pituitary-thyroid axis as well as having a great number of well defined extrathyroidal functions. Studies in experimental animals have shown, that TRH also has a role as a neuromodulator within the autonomous nervous system. In this study we analyzed the effects following peripheral administration of TRH (200 micrograms, 400 micrograms) in patients with endocrinological disorders and in healthy females and males. By means of a questionnaire, patients were asked about possible (side-) effects; ventilatory and cardiovascular monitoring was performed during steady state. The pulsatile TSH-secretion pattern was …

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsendocrine system diseasesEndocrinology Diabetes and MetabolismThyrotropin-releasing hormoneThyrotropinStimulationEndocrine System DiseasesNorepinephrine (medication)Pituitary thyroid axisEndocrinologyHeart RateInternal medicineSurveys and QuestionnairesHeart rateInternal MedicinemedicineHumansThyrotropin-Releasing Hormonebusiness.industryRespirationThyroidGeneral Medicinemedicine.anatomical_structureEpinephrineEndocrinologyFemalebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHormoneExperimental and clinical endocrinology
researchProduct

Gonadotropin and Testosterone Secretion in Normal Human Males After Stimulation With Gonadotropin-Releasing Hormone (Gnrh) or Potent Gnrh Analogs Usi…

1978

Gonadotropin-releasing hormone (GnRH) and some potent long-acting GnRH analogs, applied by different routes of administration, were tested in six healthy human males. The effects on gonadotropin secretion were compared with the one after intravenous (i.v.) bolus injection of 25 microgram of GnRH. The net increase of luteinizing hormone (deltaLH) in serum produced by 25 microgram of GnRH i.v. was matched by subcutaneous (s.c.) injection of 100 microgram of GnRH, dissolved in 20% gelatin or without gelatin; 5 microgram of D-Ser (TBU)6-des-Gly10-GnRH-ethylamide i.v.; 5 microgram of D-Leu6-des-Gly10-GnRH-ethylamide i.v.; and 50 microgram of D-Trp6-des Gly10-GnRH-ethylamide given pernasally (p.n…

AdultMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classMicrogramStimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneInternal medicinemedicineHumansInfusions ParenteralTestosteroneAdministration IntranasalChemistryObstetrics and GynecologyLuteinizing HormoneHormonesGonadotropin secretionEndocrinologyReproductive MedicineInjections IntravenousNasal administrationFollicle Stimulating HormoneGonadotropinLuteinizing hormonePituitary Hormone-Releasing Hormoneshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

Subclinical hyperthyroidism due to a thyrotropin receptor (TSHR) gene mutation (S505R).

2006

Aim: To identify the molecular defect by which non-autoimmune subclinical hyperthyroidism was caused in a 6-mo-old infant who presented with weight loss. Methods: Congenital non-autoimmune hyperthyroidism is caused by activating germline mutations in the thyrotropin receptor (TSHR) gene. Therefore, the TSHR gene was sequenced directly from the patient's genomic DNA. Results: Molecular analysis revealed a heterozygous point mutation (S505R) in the TSHR gene as the underlying defect. Conclusion: A constitutively activating mutation in the TSHR gene has to be considered not only in patients with severe congenital non-autoimmune hyperthyroidism, but also in children with subclinical non-autoimm…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesAsymptomaticHyperthyroidismThyrotropin receptorTSHR Gene MutationGermline mutationInternal medicineMedicineMissense mutationHumansPoint MutationGeneSubclinical infectionbusiness.industryPoint mutationInfantReceptors ThyrotropinGeneral Medicineeye diseasesPedigreeEndocrinologyPediatrics Perinatology and Child HealthCancer researchFemalemedicine.symptombusinesshormones hormone substitutes and hormone antagonistsActa paediatrica (Oslo, Norway : 1992)
researchProduct

Neuroendocrine response to antipsychotics: effects of drug type and gender

1999

Abstract Background: To study the influences of drug type and gender on the neuroendocrine response to neuroleptic treatment, we compared the endocrine actions of two neuroleptics with different receptor affinity profiles—a substituted benzamide, amisulpride, a selective D 2 -like dopamine antagonist; and a thioxanthene, flupenthixol, a mixed D 1 /D 2 -like antagonist also blocking serotonin, H 1 , and D 1 receptors—on anterior pituitary hormone secretion in schizophrenic patients (DSM-III-R). Methods: Blood was withdrawn at 15-min intervals to assess basal secretion of prolactin, growth hormone (GH), and thyroid-stimulating hormone (TSH). Four hundred micrograms of thyrotropin-releasing ho…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesThyrotropinThyrotropin-releasing hormoneFlupenthixolPharmacologySex FactorsDouble-Blind MethodAnterior pituitaryThyroid-stimulating hormoneInternal medicinemedicineHumansAmisulprideBiological PsychiatryHuman Growth Hormonebusiness.industryDopamine antagonistNeurosecretory SystemsProlactinProlactinFlupenthixolmedicine.anatomical_structureEndocrinologySchizophreniaFemaleSchizophrenic PsychologyAmisulprideSulpiridebusinesshormones hormone substitutes and hormone antagonistsAntipsychotic Agentsmedicine.drugHormoneBiological Psychiatry
researchProduct

Stimulation of Spermatogenesis and Biological Paternity by Intranasal (Low Dose) Gonadotropin-Releasing Hormone (GnRH) in a Male with Kallmann's Synd…

1987

Intranasal (in) GnRH spray caused induction and maintenance of spermatogenesis and biological paternity in a 28-yr-old man with Kallmann's syndrome. Prior treatment had included GnRH analog administration, which failed to induce puberty, and testosterone (T) enanthate weekly. Prior hCG/human menopausal gonadotropin therapy had resulted in high normal serum T levels and near-normal semen quality, but during subsequent hCG therapy, spermatogenesis markedly decreased. The patient had then received 250 mg T enanthate/month for 2 yr and 7 months; it was discontinued 7 weeks before the in GnRH study began. At its start (July 1984) the subject's testis size was 7 mL, and he had azoospermia, low se…

AdultMaleendocrine systemmedicine.medical_specialtymedicine.drug_classKallmann syndromeEndocrinology Diabetes and MetabolismClinical BiochemistryPaternityGonadotropin-releasing hormoneBiologyBiochemistryOlfaction DisordersEndocrinologyInternal medicinemedicineHumansSpermatogenesisTestosteroneAzoospermiaHypogonadismBiochemistry (medical)Syndromemedicine.diseaseSpermStimulation ChemicalEndocrinologyGonadotropinMenotropinsPituitary Hormone-Releasing HormonesSpermatogenesisGonadotropinshormones hormone substitutes and hormone antagonistsThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Insulin-like growth factor 1 and pressure load in hypertensive patients

1996

To verify the effect of a pressure load on the production of Insulin-like Growth Factor 1 (IGF1) in essential hypertensives, we studied 15 patients and 8 normotensive controls before and during orthostatism. Upright standing was characterized both in normals and in hypertensives by significant higher rate-pressure product [RPP = systolic blood pressure (mm Hg) x heart rate (beats/min)]. Proportional increases of RPP were significantly related to IGF1 values at the end of orthostatism and to proportional increases of IGF1 in hypertensive group but not in normotensive one. Our results confirm that IGF1 plasma levels in hypertensive patients are related to pressure load.

AdultMaleendocrine systemmedicine.medical_specialtymedicine.medical_treatmentPostureRadioimmunoassayBlood PressureBiological effectHypotension OrthostaticInsulin-like growth factorHeart RateInternal medicineHeart rateInternal MedicineHumansMedicineInsulin-Like Growth Factor IHypertensive groupbusiness.industryPlasma levelsBlood pressureEndocrinologyPressure loadHypertensionFemalebusinesshormones hormone substitutes and hormone antagonistsAmerican Journal of Hypertension
researchProduct

Testicular Sperm Extraction (TESE) and Intracytoplasmic Sperm Injection (ICSI) in Hypogonadotropic Hypogonadism with Persistent Azoospermia After Hor…

2004

Purpose: We aimed to retrieve testicular sperm to be employed on intracytoplasmic sperm injection (ICSI) cycles on a male affected of hypogonadotropic hypogonadism (HH) that remained azoospermic after long-time hormonal treatment. Methods: Design. We initially performed hormonal therapy using gonadotropins to achieve spermatogenesis. After several semen analyses, we weighed the possibility of looking for testicular spermatozoa for ICSI. Setting. A private university-affiliated setting. Patient. A 30-years-old man diagnosed 10 years ago to suffer from idiopathic, prepubertal HH. Interventions. Gonadotrophin treatment was initiated with hCG and follicle stimulating hormone (FSH). Testicular s…

AdultMaleendocrine systemmedicine.medical_treatmentSemenArticleIntracytoplasmic sperm injectionGonadotropin-Releasing HormoneAndrologyFollicle-stimulating hormonePregnancyHypogonadotropic hypogonadismGeneticsmedicineHumansTestosteroneSperm Injections IntracytoplasmicSpermatogenesisreproductive and urinary physiologyGenetics (clinical)CryopreservationAzoospermiaurogenital systembusiness.industryHypogonadismPregnancy OutcomeObstetrics and GynecologyOligospermiaGeneral MedicineLuteinizing Hormonemedicine.diseaseSpermatozoaSpermTesticular sperm extractionReproductive MedicineFemaleFollicle Stimulating HormoneLuteinizing hormonebusinesshormones hormone substitutes and hormone antagonistsSemen PreservationDevelopmental BiologyJournal of Assisted Reproduction and Genetics
researchProduct

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Allelic variants of IL1R1gene associate with severe hand osteoarthritis

2010

Background In search for genes predisposing to osteoarthritis (OA), several genome wide scans have provided evidence for linkage on 2q. In this study we targeted a 470 kb region on 2q11.2 presenting the locus with most evidence for linkage to severe OA of distal interphalangeal joints (DIP) in our genome wide scan families. Methods We genotyped 32 single nucleotide polymorphisms (SNPs) in this 470 kb region comprising six genes belonging to the interleukin 1 superfamily and monitored for association with individual SNPs and SNP haplotypes among severe familial hand OA cases (material extended from our previous linkage study; n = 134), unrelated end-stage bilateral primary knee OA cases (n =…

AdultMalelcsh:Internal medicineLinkage disequilibriumLINKAGE DISEQUILIBRIUMlcsh:QH426-470Hand JointsNF-KAPPA-BSingle-nucleotide polymorphismLocus (genetics)KNEE OSTEOARTHRITISBiologyRADIOGRAPHIC SIGNSPolymorphism Single NucleotideSeverity of Illness IndexGenomeCHROMOSOME 2QINTERLEUKIN-1 RECEPTOR ANTAGONIST03 medical and health sciences0302 clinical medicineOsteoarthritisGeneticsHumansSNPGenetic Predisposition to DiseaseGenetics(clinical)Allelelcsh:RC31-1245GeneAllelesPOLYMORPHISMSGenetics (clinical)AgedHAPLOTYPE RECONSTRUCTION030304 developmental biologyReceptors Interleukin-1 Type I030203 arthritis & rheumatologyGenetics0303 health sciencesHaplotypeCLUSTERMiddle Aged314 Health sciences3. Good healthlcsh:GeneticsCase-Control StudiesDISC DEGENERATIONFemaleResearch ArticleBMC Medical Genetics
researchProduct

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

2018

Aims Aim of this study was to associate concentration of naltrexone and its major active metabolite 6β-naltrexol in blood with therapeutic outcome during treatment with naltrexone in subjects with alcohol dependence. Treatment with the μ-opiate receptor antagonist naltrexone has been shown to reduce craving for alcohol and alcohol intake in patients suffering from alcohol dependence. Short summary This article shows the use of therapeutic drug monitoring in alcohol dependent patients, who are treated with naltrexone. The plasma concentrations of naltrexone and 6β-naltrexol showed high inter-individual variability. They were predictive for treatment response, as they correlated significantly…

AdultMalemedicine.drug_classAcamprosateNarcotic Antagonists030508 substance abuseCravingAlcoholPharmacologyNaltrexone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodReference ValuesmedicineHumansActive metaboliteCravingEthanolmedicine.diagnostic_testbusiness.industryAlcohol dependenceGeneral MedicineMiddle AgedReceptor antagonistNaltrexoneAlcoholismTreatment OutcomechemistryTherapeutic drug monitoringDrug Therapy CombinationFemalemedicine.symptomDrug Monitoring0305 other medical sciencebusiness030217 neurology & neurosurgerymedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct